CWCI: Long COVID Accounts for Three Quarters of California Workers' Comp COVID Claim Payments
Long COVID claims comprised only 4.7% of all California workers' comp COVID claims but accounted for 82% of COVID claim medical treatment dollars.
While the number of new COVID claims in California workers' compensation has gone from a flood shortly after Governor Newsom declared a COVID-19 state of emergency in March 2020 to a trickle over the last year, the new study comes amid growing concern about a potential COVID surge after the CDC adopted new guidelines that may make it more difficult to obtain COVID-19 vaccines just as the summer travel season hits and the new NB.18.1 COVID variant has been detected in multiple locations around the U.S. The study, based on a review of 126,397 insured and self-insured COVID-19 claims found that most were relatively inexpensive due to little to no medical intervention (only 14.6% involved medical treatment), but 4.7% – or nearly 6,000 of them – were Long COVID claims that involved long-term medical conditions that impeded or prevented the claimants from returning to their jobs and resulted in significant costs. Medical payments for the COVID-19 claims in the study sample totaled $128.4 million, with Long COVID claims accounting for $105.5 million, or 82.1%; while total payments on the COVID-19 claims, including medical treatment, indemnity costs, and expenses, were $350.6 million, with Long COVID claims consuming $258.3 million, or 73.7%.
Overall, average medical payments were 105 times higher on Long COVID cases than on shorter duration COVID claims, and average indemnity payments were 37 times higher. Long COVID claim payments were significantly higher regardless of the body part involved, though the difference was most pronounced for injuries involving the lungs, multiple body parts, and 'other' body parts. The top 10 diagnostic categories for Long COVID claims encompassed a wide range of organ systems, including respiratory (17.8%); circulatory (9.0%); nervous (8.7%); connective, soft tissue and bone disorders (5.2%); endocrine systems (4.9%); as well as mental health (4.4%), and digestive conditions (3.4%). Together the top 10 diagnostic categories associated with the Long COVID claims in the study sample accounted for 80.3% of all the diagnoses on these claims, highlighting the multisystem nature of Long COVID.
The Institute has included more details and graphics from the study in a report, Long COVID-19 Claim Characteristics and Treatment in California Workers' Compensation. CWCI members and subscribers can log on to www.cwci.org, to access the report under the Research tab on the home page, others can purchase a copy from CWCI's online Store.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
34 minutes ago
- Business Wire
TVCMALL at 17: Trusted One-Stop China Wholesale B2B Partner for Mobile Accessories
SHENZHEN, China--(BUSINESS WIRE)--Now in its 17th year, TVCMALL—China's one-stop B2B wholesale platform—empowers global retailers with more efficient, smoother, and more flexible solutions, especially in the mobile accessories sector. Why 3 Million Global Retailers Choose TVCMALL? 1. Efficient One-Stop Wholesale Solution, Tailored for Real Retailers As a leading one-stop B2B wholesale platform from China, TVCMALL combines sourcing, customization, dropshipping, and marketing support—streamlining procurement to save time, cost, and complexity. One strong partner instead of many, TVCMALL offers 3–5 day lead times and value-added services like smart recommendations, labeling, and repackaging—helping businesses grow with fewer resources. 2. Better Product Selection, Made Easy at TVCMALL TVCMALL offers over 1 million SKUs and adds 10,000+ new arrivals weekly. Its AI-powered system highlights trending products for faster, smarter sourcing. 95% of items have no MOQ—wholesale pricing starts from just one piece. This low-risk model helps sellers test products, reduce inventory pressure, and grow flexibly. Backed by 10,000+ verified suppliers—including trusted brands like TORRAS, DUX DUCIS, CaseMe, JOYROOM, Essager, QIALINO, BOBOVR, Lenovo and Nillkin—TVCMALL ensures reliable quality and stable supply, earning the trust of over 2,000 retail chains worldwide. 3. 30+ Leading European B2C Webshops Choose TVCMALL as a Trusted Partner With 17 years of wholesale experience, TVCMALL has become a trusted partner to over 30 leading European B2C webshops and global retail brands. Notable partners include Liverpool and Qualcomm, supported through TVCMALL's customization and wholesale solutions. Backed by secure payments, a 30-day DOA guarantee, and 1-on-1 VIP support, TVCMALL delivers reliable fulfillment and professional service—helping retailers reduce risk and grow with confidence. That's why it now sells over 10 million phone cases annually, reflecting its strength in mobile accessories and supply chain stability. Wholesale Mobile Accessories from China, All at TVCMALL TVCMALL is more than a supplier—it's a reliable wholesale partner for global online sellers, mobile accessory retailers, and brick-and-mortar chains. Celebrating its 17th anniversary, the platform now features curated brand zones and eco-certified products to meet the rising demand for sustainability across markets like Europe. By expanding product selection, reducing sourcing risks, and delivering faster, smoother service with green supply options, TVCMALL is shaping a more professional and efficient future for mobile accessories wholesale.
Business Wire
2 hours ago
- Business Wire
OPEX® Corporation推出Cortex® Sort-to-Order™集成软件套件，助力简化订单履行流程
新泽西州穆尔斯敦--(BUSINESS WIRE)--(美国商业资讯)-- OPEX® Corporation 是下一代自动化领域的全球领导者，为仓储、文档和邮件自动化提供创新解决方案。该公司今日宣布推出 Cortex® Sort-to-Order™ (S2O)软件套件，旨在为其分拣解决方案提供更高级别的功能。这款功能强大的软件套件可充分释放OPEX的 Sure Sort® 和 Sure Sort® X 仓储自动化系统的订单管理能力——优化货位分配、缩短履行时间、提高订单准确性、提供实时分析，并支持与现有仓储及订单管理系统直接通信。 OPEX仓储自动化部门总裁Alex Stevens表示：'我们一直在不断改进产品组合，而Cortex S2O正是这一努力的成果。这款新软件套件显著提升了员工的操作体验，为客户提供了一站式集成解决方案。它帮助企业更智能、更快速地开展工作，更好地确保每一笔订单都能完整、准确且按时履行。' OPEX Cortex S2O软件套件通过智能、易用的界面管理工作流程和订单履行，实现OPEX Sure Sort或OPEX Sure Sort X与任何仓储管理系统(WMS)或订单管理系统(OMS)的无缝集成，其功能和优势众多。 借助Cortex S2O，每位系统操作员都拥有专属应用程序，可在腕戴式电脑上运行，使操作员能轻松扫描、确认完整订单，并通过将新容器登记至分拣位置来补充分拣目的地的库存。该系统智能管理货位分配——战略性地拆分和定位订单以平衡机器性能，并能将业务逻辑应用于分拣位置，同时提升操作员效率。必要时，它还包含手动货位分配的覆盖功能，并允许无法在机器上处理的物品通过虚拟移动库存的方式，在自动化拣选墙上完成分拣。 该软件套件指导操作员完成质量审核和异常处理（如物品缺失）。系统全面控制可视化灯光拣选(PTL)，指引操作员前往需要关注的位置。凭借内置的检查和主动质量控制审核功能，企业能够有效防止订单不完整或错误，降低退货率及相关成本，提升整体客户满意度。 OPEX产品负责人Monty McVaugh表示：'Cortex S2O提供的全面运营分析帮助企业清晰了解处理效率、订单停留时间和操作员工作效率。自动化报告能显示订单及合并流程的进展情况，让企业了解所涉及的时间和精力。这有助于基于数据做出决策，持续优化运营并提高整体仓储效率。' Cortex S2O可同时管理多达12个分拣系统，支持多达50名操作员和12名管理人员。它具备多语言能力（包括英语、西班牙语、韩语等），并支持多种通信方式（包括数据库到数据库传输和平面文件传输）。其可扩展设计能随着业务增长适应订单量、货位配置和用户访问量的增加。此外，培训快速简便，有助于克服对变革的抵触情绪，确保跨代员工群体顺利采用。 Cortex S2O适用于小型、中型和大型企业。它减轻了客户IT资源在系统集成方面的负担，将物品交易系统转变为订单处理系统。 作为OPEX仓储自动化技术组合的最新成员，Cortex S2O加入了该公司的 Cortex® 设备管理和订单履行软件平台，该平台旨在为OPEX的 Perfect Pick® 、 Perfect Pick® HD 和 Infinity® 仓储自动化解决方案提供支持。 2025年，OPEX迎来成立50周年。五十年来，该公司一直是全球客户值得信赖的合作伙伴，为他们提供定制化、可扩展的解决方案，改变业务运营方式。公司持续提供跨代的行业专业知识，一流自动化能力和先进工程技术的成熟开发经验，以及追求卓越的传统。 关于OPEX OPEX® Corporation 是下一代自动化领域的全球领导者，为仓库、文件和邮件自动化提供创新、独特的解决方案。公司总部位于新泽西州穆尔斯敦，在新泽西州彭索金、德州普莱诺、法国、德国、瑞士、英国和澳大利亚均设有工厂。OPEX拥有近1600名员工，他们不断重新构想并提供定制化且可扩展的技术解决方案，以解决当下及未来的业务挑战。2025年是该公司在Stevens家族数代人拥有和领导下的50周年纪念。 免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
Business Wire
3 hours ago
- Business Wire
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ('Debiopharm'), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. 'The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm's existing collaboration studying the combination of lunresertib and Debio 0123,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation. We remain focused on two ongoing Phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor.' Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib. 'We are excited to enter into this worldwide license agreement with Repare for lunresertib. Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,' said Bertrand Ducrey, CEO of Debiopharm. 'We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult to treat cancers.' Continued Prioritization of RP-3467 and RP-1664 Moving forward, Repare will remain focused on the advancement of its two ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Polθ) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations, alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 alone and in combination with olaparib is expected in the third quarter of 2025. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 is expected in the fourth quarter of 2025. About Repare Therapeutics Inc. Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Debiopharm's Commitment to Patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit Follow us, we are on LinkedIn. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of lunresertib to Debiopharm, including the potential benefits of the transaction and the achievement and receipt of milestone payments and royalties under the license agreement; the Company's anticipated cash runway; the timing, progress and results of the Company's ongoing Phase 1 LIONS and POLAR clinical trials; and the potential, tolerability, efficacy and clinical progress of the Company's product candidates, including the potential of lunresertib to treat patients with difficult-to-treat solid tumors as a monotherapy or in combination with Debio 0123. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ("AMF") on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at
